KR880012221A - 에스테르 또는 아미드를 활성성분으로 함유하는 약제 조성물 - Google Patents

에스테르 또는 아미드를 활성성분으로 함유하는 약제 조성물 Download PDF

Info

Publication number
KR880012221A
KR880012221A KR1019880004073A KR880004073A KR880012221A KR 880012221 A KR880012221 A KR 880012221A KR 1019880004073 A KR1019880004073 A KR 1019880004073A KR 880004073 A KR880004073 A KR 880004073A KR 880012221 A KR880012221 A KR 880012221A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
ester
acid
amide
composition according
Prior art date
Application number
KR1019880004073A
Other languages
English (en)
Inventor
김순이
가주히사 다께다
세이예 사사타니
Original Assignee
사노 가즈오
오노 야꾸힝 고교 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노 가즈오, 오노 야꾸힝 고교 가부시끼가이샤 filed Critical 사노 가즈오
Publication of KR880012221A publication Critical patent/KR880012221A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells

Abstract

내용 없음

Description

에스테르 또는 아미드를 활성성분으로 함유하는 약제 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제 1도 내지 3도는 소장내에서의 본 발명의 약제 조성물중의 활성성분의 시간에 따른 잔존률의 변화를 나타낸 것이다.

Claims (22)

  1. 에스테르 또는 아미드(글리코사이드, 사이클로스포린, 항생물질 및 니페디핀은 제외)가 중쇄 글리세라이드 또는 이들 중 2개 이상의 혼합물중엔 현탁 또는 용해되어 있음을 특징으로 하는 약제 조성물.
  2. 제 1항에 있어서, 에스테르가 벤조산의 에스테르인 약제 조성물.
  3. 제 2항에 있어서, 벤조산의 에스테르가 일반식(I)의 화합물 또는 이의 비독성산-부가염인 약제 조성물.
    상기 식에서, R은 유기 그룹이다.
  4. 제 3항에 있어서, R이 치환된-방향족 그룹인 약제 조성물.
  5. 제 4항에 있어서, 구아니디노벤조산의 에스테르가 p-(p-구아니디노벤조일옥시)페닐아세트산 N,N-디메틸카바모일메틸 에스테르, p-구아니디노벤조산 p-설파모일페닐 에스테르 또는 p-구아니디노벤조산 6-미디노나프트-2-일에스테르이거나 이의 비독성 산-부가염인 약제 조성물.
  6. 제 3항에 있어서, 벤조산의 에스테르가 p-구아니디노벤조산 메틸에스테르 또는 이의 비독성 산-부가염인 약제 조성물.
  7. 제 2항에 있어서, 벤조산의 에스테르가 아스피린 또는 살리실산 에틸에스테르인 약제 조성물.
  8. 제 1항에 있어서, 에스테르가 트롬복산 동족체의 에스테르인 약제 조성물.
  9. 제 8항에 있어서, 트롬복산 동족체의 에스테르가 7-(3-토실아미노바이사이클로[2.2.1]헵탄-2-일)5Z 헵테노산의 알킬에스테르인 약제 조성물.
  10. 제 1항에 있어서, 아미드가 프로스타글란딘 동족체의 아미드인 약제 조성물.
  11. 제 10항에 있어서, 프로스타글란딘 동족체의 아미드가 아미노산 함유된 6-케토-16S, 18S-에타노-20-에틸-PGE1의 아미드인 약제 조성물.
  12. 제 1항에 있어서, 아미드가 벤조산의 아미드인 약제 조성물.
  13. 제 1항에 있어서, 아미드가 트롬복산 동족체의 아미드인 약제 조성물.
  14. 제 13항에 있어서, 트롬복산 동족체의 아미드가 아미노산 함유된 7-(3-토실아미노바이사이클로[2.2.1]헵탄-2-일)-5Z-헵테노산의 아미드인 약제 조성물.
  15. 제 1항에 있어서, 아미드가 아미도 결합 함유-프롤리날 또는 티아졸리딘 유도체인 약제 조성물.
  16. 제 15항에 있어서, 아미도 결합 함유-프롤리날 또는 티아졸리딘 유도체가 N-[3-[N-(4-클로로벤질)카바모일]프로파노일]-L프롤리날인 약제 조성물.
  17. 제 1항에 있어서, 중쇄 글리세라이드가 카프릴산의 글리세라이드 또는 카프르산의 글리세라이드인 약제 조성물.
  18. 제 17항에 있어서, 중쇄 글리세라이드가 글리세릴 모노카릴레이트, 글리세릴 디카프릴레이트 또는 글리세릴 트리카르릴레이트이거나 이의 혼합물인 약제 조성물.
  19. 제 1항에 있어서, 캡슐에 충진된 약제 조성물.
  20. 제 19항에 있어서, 캡슐이 장용성 피막으로 피복됨을 특징으로 하는 약제 조성물.
  21. 제 20항에 있어서, 장용성 피막이 카복시메틸에틸 셀룰로오즈, 하이드록시프로필메틸 셀룰로오즈 아세테이트 석시네이트 또는 인지질임을 특징으로 하는 약제 조성물.
  22. 에스테르 또는 아미드(글리코사이드, 사이클로스포린, 항생물질 및 니페디핀은 제외)를 중쇄 글리세라이드 또는 이들중 2개 이상의 혼합물에 현탁 또는 용해시킴을 특징으로 하여, 약제 조성물을 제조하는 방법.
    ※ 참고사항 : 최초출원내용에 의하여 공개하는 것임.
KR1019880004073A 1987-04-13 1988-04-11 에스테르 또는 아미드를 활성성분으로 함유하는 약제 조성물 KR880012221A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP8878587 1987-04-13
JP?62-88785 1987-04-13

Publications (1)

Publication Number Publication Date
KR880012221A true KR880012221A (ko) 1988-11-26

Family

ID=13952501

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880004073A KR880012221A (ko) 1987-04-13 1988-04-11 에스테르 또는 아미드를 활성성분으로 함유하는 약제 조성물

Country Status (7)

Country Link
US (3) US4889723A (ko)
EP (1) EP0287036B1 (ko)
KR (1) KR880012221A (ko)
AT (1) ATE62419T1 (ko)
DE (1) DE3862337D1 (ko)
ES (1) ES2033985T3 (ko)
GR (1) GR3001762T3 (ko)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1263840B (it) * 1993-03-30 1996-09-04 Giuseppe Furiosi Formulazioni orali di ubidecarenone in forma di capsule
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US5834017A (en) * 1995-08-25 1998-11-10 Sangstat Medical Corporation Oral cyclopsporin formulations
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5827822A (en) * 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
EP0893437A4 (en) * 1996-04-10 2000-12-27 Ono Pharmaceutical Co GUANIDINO TRYPTASE INHIBITOR
WO1998001117A1 (en) 1996-07-08 1998-01-15 Edward Mendell Co., Inc. Sustained release matrix for high-dose insoluble drugs
WO1998026803A1 (fr) * 1996-12-19 1998-06-25 Daiichi Pharmaceutical Co., Ltd. Composition pharmaceutique pour administration par voie orale
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
AU759641B2 (en) * 1998-08-19 2003-04-17 Skyepharma Canada Inc. Injectable aqueous dispersions of propofol
CA2358448C (en) 1998-12-30 2009-02-10 Dexcel Ltd. Dispersible concentrate for the delivery of cyclosporin
US6849605B1 (en) * 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
AU3864000A (en) * 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
WO2000051623A2 (en) 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
JP3893058B2 (ja) * 1999-09-30 2007-03-14 ペンウェスト ファーマシューティカルズ カンパニー 高度に可溶性の薬物のための徐放性マトリックス系
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US20040220242A1 (en) * 2003-05-02 2004-11-04 Leland Shapiro Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
JP2007504144A (ja) 2003-08-26 2007-03-01 ザ リージェンツ オブ ザ ユニバーシティー オブ コロラド ア ボディー コーポレイト セリンプロテアーゼ活性阻害因子、ならびに細菌感染の治療法および組成物におけるその使用方法
BRPI0518242A2 (pt) * 2004-10-26 2008-11-11 Allergan Inc mÉtodos terapÊuticos e de liberaÇço de agonistas de prostaglandina ep4
CN103957888B (zh) * 2011-09-29 2017-11-21 PLx 制药公司 用于将药物沿胃肠道靶向释放的pH依赖性载体、其组合物及其制备和应用
CN115666523A (zh) 2020-03-26 2023-01-31 Plx 奥普科有限公司 能够进行pH依赖性重构的药物载体及其制备和使用方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1544576A (en) * 1976-07-12 1979-04-19 Kali Chemie Pharma Gmbh Enterally highly-absorbable preparations of cardiac glycosides which by themselves are absorbable with difficulty and process for the production of such preparations
JPS53136513A (en) * 1977-05-06 1978-11-29 Ono Pharmaceut Co Ltd Stabilization of prostaglandin-x-related compounds
FI65914C (fi) * 1978-03-07 1984-08-10 Sandoz Ag Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
US4722941A (en) * 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
DE3000377A1 (de) * 1980-01-07 1981-07-09 Boehringer Mannheim Gmbh, 6800 Mannheim Neue sulfonamide, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
US4305936A (en) * 1980-10-09 1981-12-15 Dermik Laboratories Topical corticosteroid formulations
DE3042975A1 (de) * 1980-11-14 1982-09-09 Lucas Meyer GmbH & Co, 2000 Hamburg Mikrodispersion mit einem wirkstoff und/oder einem reagens in salzform als disperser phase
JPS57197214A (en) * 1981-05-29 1982-12-03 Tanabe Seiyaku Co Ltd Rapid-releasing microcapsule and its preparation
US4525339A (en) * 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
DE3411910A1 (de) * 1984-03-30 1985-10-10 Warner-Lambert Co., Morris Plains, N.J. Galenische zubereitung
DE3421468A1 (de) * 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
US4716178A (en) * 1985-07-22 1987-12-29 Riker Laboratories, Inc. Substituted di-t-butylphenols

Also Published As

Publication number Publication date
ATE62419T1 (de) 1991-04-15
EP0287036A2 (en) 1988-10-19
EP0287036B1 (en) 1991-04-10
DE3862337D1 (de) 1991-05-16
US5110602A (en) 1992-05-05
US5004612A (en) 1991-04-02
ES2033985T3 (es) 1993-04-01
US4889723A (en) 1989-12-26
GR3001762T3 (en) 1992-11-23
EP0287036A3 (en) 1988-11-30

Similar Documents

Publication Publication Date Title
KR880012221A (ko) 에스테르 또는 아미드를 활성성분으로 함유하는 약제 조성물
US4525339A (en) Enteric coated oral dosage form
GB1485676A (en) Pharmaceutical formulations containing l-dopa or derivatives thereof
KR920019359A (ko) 담즙산을 함유하는 경구용 위내성 의약 포뮬레이션
KR920019358A (ko) 담즙산 염을 함유하는 경구용 위 내성 의약 포뮬레이션
FI20000171A (fi) Itse-emulgoituvan valmisteen muodossa oleva farmaseuttinen koostumus lipofiilisia yhdisteitä varten
AR017801A1 (es) Una composicion de preconcentrado en microemulsion que contiene ciclosporina, y una formulacion farmaceutica que la comprende
NO980047D0 (no) Blanding for tildeling av et polart medikament i kolon
DK1273289T3 (da) Farmaceutiske sammensætninger indeholdende ascomycinderivater
CA2294031A1 (en) SELF-EMULSIFYING FORMULATION FOR LIPOPHILIC COMPOUNDS
CN1301147A (zh) 可用于牙周的胶凝药物组合物
ATE301989T1 (de) Orale pharmazeutische zusammensetzung mit einem wirkstoff, der bei seiner ersten darmpassage starken wirkungen ausgesetzt werden kann
RU98110641A (ru) Ингибиторы тромбина
KR920019360A (ko) 담즙산과 그 염을 함유하는 경구용 제어 방출 위 내성 의약 포뮬레이션
CA2541292C (en) Vegetable oil formulations for retinoid-containing soft gelatin capsules
ES2059388T3 (es) N-(2-(4-carboximetoxifenil)-1-metiletil)-2-hidroxi-2-(3-clorofenil)etanamina, el ester metilico, la sal y los estereoisomeros de los mismos.
KR890701572A (ko) 고리형 아미노산의 유도체,이들의 염, 이들을 함유하는 약제조성물 및 이들의 제조방법.
US5707651A (en) Soft capsules containing dinreburnamenine compounds
JP2537658C (ko)
RU96117652A (ru) Двуслойные препараты
JPS6425715A (en) Novel pharmaceutical containing esters or amides as active ingredient
KR880004815A (ko) 약제학적 조성물 및 이의 용도
TH28372B (th) สารผสมทางเภสัชกรรมที่มีสารยับยั้งโปรตีนเอส
BE810668A (fr) Esters d'acides du phosphore et leur application en tant que matieres actives de produits pesticides
RU95120104A (ru) Производное серина

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid